Rhabdomyosarcoma staging: Difference between revisions

Jump to navigation Jump to search
Line 14: Line 14:
*** Based on tumor size, node involvement, and metastasis
*** Based on tumor size, node involvement, and metastasis
***Categorized in four groups
***Categorized in four groups
{| class="wikitable"
|+Clinical group staging
!Stage
!Description
|-
|I
|
* Contain 13% of all cases
* Localized region
* Complete resection
* No nodal involvement
|-
|II
|
* Contain 20% of all cases
* IIA group: Complete resection with microscopic residual disease/ no nodal involvement
* IIB group: Complete resection with no microscopic residual diseases/ regional nodal involvement
* IIC group: Complete resection with microscopic residual disease/ regional nodal involvement
|-
|III
|
* Contain 48% of all cases
* Incomplete resection or biopsy
* Gross residual disease
|-
|IV
|
* Contain 18% of all cases
* Distant metastasis at time of diagnosis
|}


==References==
==References==

Revision as of 15:48, 1 February 2019

Rhabdomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Rhabdomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Rhabdomyosarcoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rhabdomyosarcoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rhabdomyosarcoma staging

CDC on Rhabdomyosarcoma staging

Rhabdomyosarcoma staging in the news

Blogs on Rhabdomyosarcoma staging

Directions to Hospitals Treating Rhabdomyosarcoma

Risk calculators and risk factors for Rhabdomyosarcoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]

Overview

According to the Children's Oncology Group, there are four stages of rhabdomyosarcoma based on the location of tumor, size of tumor, involvement of lymph nodes, and metastasis.

Staging of rhabdomyosarcoma

  • There are two staging classification for rhabdomyosarcoma:[1][1]
    • Clinical group (CG)
      • Created by intergroup rhabdomyosarcoma study group (IRSG) in 1972
      • Based on spread of tumor cells at diagnosis and remaining disease after surgery
      • Categorized in four groups
    • Tumor, node, metastasis system (TNM)
      • Based on tumor size, node involvement, and metastasis
      • Categorized in four groups
Clinical group staging
Stage Description
I
  • Contain 13% of all cases
  • Localized region
  • Complete resection
  • No nodal involvement
II
  • Contain 20% of all cases
  • IIA group: Complete resection with microscopic residual disease/ no nodal involvement
  • IIB group: Complete resection with no microscopic residual diseases/ regional nodal involvement
  • IIC group: Complete resection with microscopic residual disease/ regional nodal involvement
III
  • Contain 48% of all cases
  • Incomplete resection or biopsy
  • Gross residual disease
IV
  • Contain 18% of all cases
  • Distant metastasis at time of diagnosis

References

  1. 1.0 1.1 Crist WM, Garnsey L, Beltangady MS, Gehan E, Ruymann F, Webber B; et al. (1990). "Prognosis in children with rhabdomyosarcoma: a report of the intergroup rhabdomyosarcoma studies I and II. Intergroup Rhabdomyosarcoma Committee". J Clin Oncol. 8 (3): 443–52. doi:10.1200/JCO.1990.8.3.443. PMID 2407808.

Template:WH Template:WS